Pembrolizumab Plus Axitinib vs Standard Treatment For mRCC

Treatment with pembrolizumab plus axitinib improved response and survival compared with sunitinib in patients with advanced, or metastatic clear-cell renal cell carcinoma.

Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news